25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Standard Biotools Inc
Buy, Hold or Sell?

Let's analyze Standard Biotools Inc together

I guess you are interested in Standard Biotools Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Standard Biotools Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Standard Biotools Inc

I send you an email if I find something interesting about Standard Biotools Inc.

1. Quick Overview

1.1. Quick analysis of Standard Biotools Inc (30 sec.)










1.2. What can you expect buying and holding a share of Standard Biotools Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
7.5%

What is your share worth?

Current worth
$1.31
Expected worth in 1 year
$2.98
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$1.67
Return On Investment
118.3%

For what price can you sell your share?

Current Price per Share
$1.41
Expected price per share
$1.21 - $2.14
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Standard Biotools Inc (5 min.)




Live pricePrice per Share (EOD)
$1.41
Intrinsic Value Per Share
$-4.26 - $-2.16
Total Value Per Share
$-2.95 - $-0.84

2.2. Growth of Standard Biotools Inc (5 min.)




Is Standard Biotools Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$489.3m-$105.9m$540.9m124.4%

How much money is Standard Biotools Inc making?

Current yearPrevious yearGrowGrow %
Making money-$31.1m-$18.9m-$12.2m-39.2%
Net Profit Margin-80.9%-72.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Standard Biotools Inc (5 min.)




2.4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Standard Biotools Inc?

Welcome investor! Standard Biotools Inc's management wants to use your money to grow the business. In return you get a share of Standard Biotools Inc.

First you should know what it really means to hold a share of Standard Biotools Inc. And how you can make/lose money.

Speculation

The Price per Share of Standard Biotools Inc is $1.41. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Standard Biotools Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Standard Biotools Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.31. Based on the TTM, the Book Value Change Per Share is $0.42 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Standard Biotools Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.07-5.1%-0.08-5.9%-0.05-3.6%-0.07-4.7%-0.05-3.8%
Usd Book Value Change Per Share-0.06-4.0%0.4229.6%-0.05-3.3%0.043.1%0.021.6%
Usd Dividend Per Share0.000.0%0.000.0%0.010.6%0.000.1%0.000.1%
Usd Total Gains Per Share-0.06-4.0%0.4229.6%-0.04-2.7%0.053.2%0.021.7%
Usd Price Per Share1.93-2.16-1.99-3.38-7.44-
Price to Earnings Ratio-6.67--7.13--9.85--21.61--47.70-
Price-to-Total Gains Ratio-34.49--9.77--56.03--50.34--243.32-
Price to Book Ratio1.47-2.39--6.84-5.87-29.53-
Price-to-Total Gains Ratio-34.49--9.77--56.03--50.34--243.32-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.41
Number of shares709
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.420.04
Usd Total Gains Per Share0.420.05
Gains per Quarter (709 shares)295.7132.35
Gains per Year (709 shares)1,182.85129.39
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10118311735124119
202366235610249248
303549353915373377
404731472220498506
505914590525622635
607097708830747764
708280827135871893
8094639454399961022
9010646106374411201151
10011829118204912451280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.060.00.00.0%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%8.032.00.020.0%13.045.02.021.7%
Dividend per Share0.00.04.00.0%3.00.09.025.0%3.00.017.015.0%3.00.037.07.5%3.00.057.05.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%8.032.00.020.0%13.045.02.021.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Standard Biotools Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0560.417-113%-0.046-17%0.044-228%0.022-349%
Book Value Per Share--1.3141.169+12%-0.285+122%0.283+365%0.262+402%
Current Ratio--3.7613.397+11%4.116-9%2.978+26%3.283+15%
Debt To Asset Ratio--0.2820.329-14%1.294-78%4.573-94%2.648-89%
Debt To Equity Ratio--0.3930.527-25%-+100%1.282-69%2.695-85%
Dividend Per Share----0%0.009-100%0.002-100%0.001-100%
Enterprise Value--892583885.440949081768.700-6%417532778.400+114%1128128702.796-21%2629260643.678-66%
Eps---0.072-0.084+16%-0.051-30%-0.066-8%-0.054-25%
Ev To Ebitda Ratio---9.607-10.269+7%-8.075-16%-42.322+341%-74.132+672%
Ev To Sales Ratio--4.9626.146-19%4.025+23%8.672-43%22.601-78%
Free Cash Flow Per Share---0.081-0.100+23%-0.035-57%-0.049-39%-0.036-55%
Free Cash Flow To Equity Per Share---0.081-0.133+64%-0.039-52%-0.020-75%-0.016-81%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---2.158--------
Intrinsic Value_10Y_min---4.261--------
Intrinsic Value_1Y_max---0.156--------
Intrinsic Value_1Y_min---0.283--------
Intrinsic Value_3Y_max---0.515--------
Intrinsic Value_3Y_min---0.981--------
Intrinsic Value_5Y_max---0.929--------
Intrinsic Value_5Y_min---1.815--------
Market Cap524885201.280-37%718459885.440802250018.700-10%739864778.400-3%1256566652.796-43%2770168593.678-74%
Net Profit Margin---0.599-0.809+35%-0.721+20%-0.871+45%-0.722+21%
Operating Margin---0.593-0.817+38%-0.679+14%-0.708+19%-0.619+4%
Operating Ratio--1.7051.803-5%1.670+2%1.7060%1.617+5%
Pb Ratio1.073-37%1.4682.387-38%-6.838+566%5.865-75%29.530-95%
Pe Ratio-4.871+27%-6.668-7.129+7%-9.848+48%-21.607+224%-47.702+615%
Price Per Share1.410-37%1.9302.155-10%1.988-3%3.376-43%7.442-74%
Price To Free Cash Flow Ratio-4.356+27%-5.963-7.129+20%-16.038+169%-33.135+456%-77.536+1200%
Price To Total Gains Ratio-25.199+27%-34.493-9.770-72%-56.032+62%-50.340+46%-243.319+605%
Quick Ratio--4.6214.107+12%4.518+2%3.275+41%3.664+26%
Return On Assets---0.040-0.052+31%-0.052+32%-0.357+804%-0.204+416%
Return On Equity---0.055-0.080+46%--100%-0.239+334%-0.253+359%
Total Gains Per Share---0.0560.417-113%-0.038-33%0.046-223%0.023-340%
Usd Book Value--489333000.000435028000.000+12%-105931750.000+122%105182150.000+365%97526875.000+402%
Usd Book Value Change Per Share---0.0560.417-113%-0.046-17%0.044-228%0.022-349%
Usd Book Value Per Share--1.3141.169+12%-0.285+122%0.283+365%0.262+402%
Usd Dividend Per Share----0%0.009-100%0.002-100%0.001-100%
Usd Enterprise Value--892583885.440949081768.700-6%417532778.400+114%1128128702.796-21%2629260643.678-66%
Usd Eps---0.072-0.084+16%-0.051-30%-0.066-8%-0.054-25%
Usd Free Cash Flow---30124000.000-37126750.000+23%-12978750.000-57%-18257950.000-39%-13567200.000-55%
Usd Free Cash Flow Per Share---0.081-0.100+23%-0.035-57%-0.049-39%-0.036-55%
Usd Free Cash Flow To Equity Per Share---0.081-0.133+64%-0.039-52%-0.020-75%-0.016-81%
Usd Market Cap524885201.280-37%718459885.440802250018.700-10%739864778.400-3%1256566652.796-43%2770168593.678-74%
Usd Price Per Share1.410-37%1.9302.155-10%1.988-3%3.376-43%7.442-74%
Usd Profit---26938000.000-31147249.750+16%-18931250.000-30%-24725399.950-8%-20160174.975-25%
Usd Revenue--44969000.00038975500.000+15%26293250.000+71%31658350.000+42%29637975.000+52%
Usd Total Gains Per Share---0.0560.417-113%-0.038-33%0.046-223%0.023-340%
 EOD+3 -5MRQTTM+24 -13YOY+14 -255Y+17 -2210Y+16 -23

3.3 Fundamental Score

Let's check the fundamental score of Standard Biotools Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.871
Price to Book Ratio (EOD)Between0-11.073
Net Profit Margin (MRQ)Greater than0-0.599
Operating Margin (MRQ)Greater than0-0.593
Quick Ratio (MRQ)Greater than14.621
Current Ratio (MRQ)Greater than13.761
Debt to Asset Ratio (MRQ)Less than10.282
Debt to Equity Ratio (MRQ)Less than10.393
Return on Equity (MRQ)Greater than0.15-0.055
Return on Assets (MRQ)Greater than0.05-0.040
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Standard Biotools Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.026
Ma 20Greater thanMa 501.535
Ma 50Greater thanMa 1001.745
Ma 100Greater thanMa 2001.796
OpenGreater thanClose1.340
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Standard Biotools Inc

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-02-17 05:56:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Standard Biotools Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Standard Biotools Inc to the Medical Devices industry mean.
  • A Net Profit Margin of -59.9% means that $-0.60 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Standard Biotools Inc:

  • The MRQ is -59.9%. The company is making a huge loss. -2
  • The TTM is -80.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-59.9%TTM-80.9%+21.0%
TTM-80.9%YOY-72.1%-8.7%
TTM-80.9%5Y-87.1%+6.2%
5Y-87.1%10Y-72.2%-14.9%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-59.9%-6.4%-53.5%
TTM-80.9%-13.7%-67.2%
YOY-72.1%-14.5%-57.6%
5Y-87.1%-14.8%-72.3%
10Y-72.2%-14.5%-57.7%
4.3.1.2. Return on Assets

Shows how efficient Standard Biotools Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Standard Biotools Inc to the Medical Devices industry mean.
  • -4.0% Return on Assets means that Standard Biotools Inc generated $-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Standard Biotools Inc:

  • The MRQ is -4.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.0%TTM-5.2%+1.2%
TTM-5.2%YOY-5.2%+0.0%
TTM-5.2%5Y-35.7%+30.6%
5Y-35.7%10Y-20.4%-15.3%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.0%-2.3%-1.7%
TTM-5.2%-3.0%-2.2%
YOY-5.2%-3.9%-1.3%
5Y-35.7%-2.8%-32.9%
10Y-20.4%-3.6%-16.8%
4.3.1.3. Return on Equity

Shows how efficient Standard Biotools Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Standard Biotools Inc to the Medical Devices industry mean.
  • -5.5% Return on Equity means Standard Biotools Inc generated $-0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Standard Biotools Inc:

  • The MRQ is -5.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.5%TTM-8.0%+2.5%
TTM-8.0%YOY--8.0%
TTM-8.0%5Y-23.9%+15.9%
5Y-23.9%10Y-25.3%+1.4%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.5%-2.9%-2.6%
TTM-8.0%-3.9%-4.1%
YOY--4.0%+4.0%
5Y-23.9%-4.0%-19.9%
10Y-25.3%-5.0%-20.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Standard Biotools Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Standard Biotools Inc is operating .

  • Measures how much profit Standard Biotools Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Standard Biotools Inc to the Medical Devices industry mean.
  • An Operating Margin of -59.3% means the company generated $-0.59  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Standard Biotools Inc:

  • The MRQ is -59.3%. The company is operating very inefficient. -2
  • The TTM is -81.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-59.3%TTM-81.7%+22.4%
TTM-81.7%YOY-67.9%-13.8%
TTM-81.7%5Y-70.8%-10.9%
5Y-70.8%10Y-61.9%-8.8%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-59.3%-13.5%-45.8%
TTM-81.7%-21.4%-60.3%
YOY-67.9%-11.8%-56.1%
5Y-70.8%-16.3%-54.5%
10Y-61.9%-16.5%-45.4%
4.3.2.2. Operating Ratio

Measures how efficient Standard Biotools Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 1.71 means that the operating costs are $1.71 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Standard Biotools Inc:

  • The MRQ is 1.705. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.803. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.705TTM1.803-0.098
TTM1.803YOY1.670+0.133
TTM1.8035Y1.706+0.098
5Y1.70610Y1.617+0.088
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7051.305+0.400
TTM1.8031.297+0.506
YOY1.6701.321+0.349
5Y1.7061.360+0.346
10Y1.6171.303+0.314
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Standard Biotools Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Standard Biotools Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 3.76 means the company has $3.76 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Standard Biotools Inc:

  • The MRQ is 3.761. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.397. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.761TTM3.397+0.363
TTM3.397YOY4.116-0.718
TTM3.3975Y2.978+0.420
5Y2.97810Y3.283-0.306
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7612.596+1.165
TTM3.3972.712+0.685
YOY4.1162.894+1.222
5Y2.9783.515-0.537
10Y3.2833.470-0.187
4.4.3.2. Quick Ratio

Measures if Standard Biotools Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Standard Biotools Inc to the Medical Devices industry mean.
  • A Quick Ratio of 4.62 means the company can pay off $4.62 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Standard Biotools Inc:

  • The MRQ is 4.621. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.107. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.621TTM4.107+0.513
TTM4.107YOY4.518-0.410
TTM4.1075Y3.275+0.833
5Y3.27510Y3.664-0.389
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6211.488+3.133
TTM4.1071.572+2.535
YOY4.5181.875+2.643
5Y3.2752.415+0.860
10Y3.6642.550+1.114
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Standard Biotools Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Standard Biotools Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Standard Biotools Inc to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.28 means that Standard Biotools Inc assets are financed with 28.2% credit (debt) and the remaining percentage (100% - 28.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Standard Biotools Inc:

  • The MRQ is 0.282. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.329. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.282TTM0.329-0.047
TTM0.329YOY1.294-0.966
TTM0.3295Y4.573-4.245
5Y4.57310Y2.648+1.926
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2820.403-0.121
TTM0.3290.406-0.077
YOY1.2940.370+0.924
5Y4.5730.429+4.144
10Y2.6480.449+2.199
4.5.4.2. Debt to Equity Ratio

Measures if Standard Biotools Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Standard Biotools Inc to the Medical Devices industry mean.
  • A Debt to Equity ratio of 39.3% means that company has $0.39 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Standard Biotools Inc:

  • The MRQ is 0.393. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.527. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.393TTM0.527-0.134
TTM0.527YOY-+0.527
TTM0.5275Y1.282-0.755
5Y1.28210Y2.695-1.413
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3930.580-0.187
TTM0.5270.623-0.096
YOY-0.551-0.551
5Y1.2820.641+0.641
10Y2.6950.717+1.978
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Standard Biotools Inc generates.

  • Above 15 is considered overpriced but always compare Standard Biotools Inc to the Medical Devices industry mean.
  • A PE ratio of -6.67 means the investor is paying $-6.67 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Standard Biotools Inc:

  • The EOD is -4.871. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.668. Based on the earnings, the company is expensive. -2
  • The TTM is -7.129. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.871MRQ-6.668+1.796
MRQ-6.668TTM-7.129+0.461
TTM-7.129YOY-9.848+2.720
TTM-7.1295Y-21.607+14.478
5Y-21.60710Y-47.702+26.095
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-4.871-1.475-3.396
MRQ-6.668-1.755-4.913
TTM-7.129-2.155-4.974
YOY-9.848-3.044-6.804
5Y-21.607-2.530-19.077
10Y-47.702-2.241-45.461
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Standard Biotools Inc:

  • The EOD is -4.356. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.963. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.129. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.356MRQ-5.963+1.606
MRQ-5.963TTM-7.129+1.166
TTM-7.129YOY-16.038+8.909
TTM-7.1295Y-33.135+26.006
5Y-33.13510Y-77.536+44.401
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-4.356-1.746-2.610
MRQ-5.963-1.987-3.976
TTM-7.129-2.233-4.896
YOY-16.038-5.598-10.440
5Y-33.135-3.825-29.310
10Y-77.536-4.975-72.561
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Standard Biotools Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 1.47 means the investor is paying $1.47 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Standard Biotools Inc:

  • The EOD is 1.073. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.468. Based on the equity, the company is underpriced. +1
  • The TTM is 2.387. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.073MRQ1.468-0.396
MRQ1.468TTM2.387-0.919
TTM2.387YOY-6.838+9.225
TTM2.3875Y5.865-3.478
5Y5.86510Y29.530-23.665
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD1.0732.131-1.058
MRQ1.4682.268-0.800
TTM2.3872.385+0.002
YOY-6.8383.050-9.888
5Y5.8654.281+1.584
10Y29.5304.589+24.941
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Standard Biotools Inc.

4.8.3. Insider Transactions

Insiders are holding 1.867% of the shares of Standard Biotools Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-08-26Casdin Partners Master Fund, LBUY1500002.15
2024-08-23Casdin Partners Master Fund, LBUY2921002.13
2024-08-21Casdin Partners Master Fund, LBUY5000001.9
2024-08-19Casdin Partners Master Fund, LBUY2500001.85
2024-08-14Casdin Partners Master Fund, LBUY12000001.59
2024-08-12Casdin Partners Master Fund, LBUY5000001.64
2024-08-09Casdin Partners Master Fund, LBUY5254081.61
2024-08-07Casdin Partners Master Fund, LBUY5000001.57
2024-08-05Casdin Partners Master Fund, LBUY2000001.58
2024-08-02Casdin Partners Master Fund, LBUY10000001.63
2024-05-22Casdin Partners Master Fund, LBUY1500002.58
2024-05-20Casdin Partners Master Fund, LBUY1000002.58
2024-05-17Casdin Partners Master Fund, LBUY3520722.56
2024-05-15Casdin Partners Master Fund, LBUY5000002.57
2024-03-04Casdin Partners Master Fund, LBUY2500002.57
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets681,539
Total Liabilities192,206
Total Stockholder Equity489,333
 As reported
Total Liabilities 192,206
Total Stockholder Equity+ 489,333
Total Assets = 681,539

Assets

Total Assets681,539
Total Current Assets453,607
Long-term Assets227,932
Total Current Assets
Cash And Cash Equivalents 210,647
Short-term Investments 155,683
Net Receivables 35,317
Inventory 42,644
Other Current Assets 9,316
Total Current Assets  (as reported)453,607
Total Current Assets  (calculated)453,607
+/-0
Long-term Assets
Property Plant Equipment 72,246
Goodwill 106,342
Intangible Assets 23,367
Long-term Assets Other 25,977
Long-term Assets  (as reported)227,932
Long-term Assets  (calculated)227,932
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities120,615
Long-term Liabilities71,591
Total Stockholder Equity489,333
Total Current Liabilities
Short-term Debt 61,035
Short Long Term Debt 54,913
Accounts payable 10,926
Other Current Liabilities 35,218
Total Current Liabilities  (as reported)120,615
Total Current Liabilities  (calculated)162,092
+/- 41,477
Long-term Liabilities
Long term Debt 299
Capital Lease Obligations 34,262
Long-term Liabilities Other 1,510
Long-term Liabilities  (as reported)71,591
Long-term Liabilities  (calculated)36,071
+/- 35,520
Total Stockholder Equity
Common Stock390
Retained Earnings -1,151,579
Accumulated Other Comprehensive Income -1,409
Other Stockholders Equity 1,641,931
Total Stockholder Equity (as reported)489,333
Total Stockholder Equity (calculated)489,333
+/-0
Other
Capital Stock390
Cash and Short Term Investments 366,330
Common Stock Shares Outstanding 371,538
Current Deferred Revenue13,436
Liabilities and Stockholders Equity 681,539
Net Debt -121,173
Net Invested Capital 544,545
Net Working Capital 332,992
Property Plant and Equipment Gross 141,869
Short Long Term Debt Total 89,474



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312008-12-312008-06-302007-12-31
> Total Assets 
54,776
49,678
32,354
32,153
0
0
22,090
24,801
94,718
85,655
82,602
79,326
70,666
64,932
117,095
113,732
113,237
111,965
114,241
116,915
424,723
417,746
410,393
407,559
395,031
389,129
378,487
371,061
354,435
342,034
320,421
306,395
292,468
278,709
291,996
287,351
269,702
259,103
252,290
303,647
291,447
283,793
269,394
264,812
290,219
282,348
322,977
324,757
305,198
289,315
2,363
275,214
271,938
441,122
414,915
390,310
371,654
355,827
339,285
323,067
777,667
708,732
681,539
681,539708,732777,667323,067339,285355,827371,654390,310414,915441,122271,938275,2142,363289,315305,198324,757322,977282,348290,219264,812269,394283,793291,447303,647252,290259,103269,702287,351291,996278,709292,468306,395320,421342,034354,435371,061378,487389,129395,031407,559410,393417,746424,723116,915114,241111,965113,237113,732117,09564,93270,66679,32682,60285,65594,71824,80122,0900032,15332,35449,67854,776
   > Total Current Assets 
50,329
44,395
29,225
28,483
0
0
18,260
20,881
90,843
80,989
76,032
70,033
56,655
55,697
105,544
101,211
98,557
80,542
86,658
104,584
178,813
127,434
132,820
155,897
155,233
143,380
145,450
144,095
137,804
127,044
108,087
96,671
86,112
79,125
96,166
94,801
81,001
75,247
71,860
127,106
111,478
106,779
96,554
96,096
82,433
78,450
122,663
117,663
96,327
78,206
2,357
72,066
73,197
250,877
229,017
208,815
194,928
183,070
170,741
158,215
547,565
480,029
453,607
453,607480,029547,565158,215170,741183,070194,928208,815229,017250,87773,19772,0662,35778,20696,327117,663122,66378,45082,43396,09696,554106,779111,478127,10671,86075,24781,00194,80196,16679,12586,11296,671108,087127,044137,804144,095145,450143,380155,233155,897132,820127,434178,813104,58486,65880,54298,557101,211105,54455,69756,65570,03376,03280,98990,84320,88118,2600028,48329,22544,39550,329
       Cash And Cash Equivalents 
34,077
28,966
17,796
14,602
0
0
5,083
5,723
55,831
10,129
11,881
13,553
8,496
9,854
66,011
58,649
61,815
32,290
20,099
35,261
101,024
43,681
30,939
33,713
36,982
23,745
28,817
29,117
42,854
35,898
32,306
35,045
44,097
39,597
60,944
58,056
41,972
39,424
35,829
95,401
65,634
24,046
25,886
21,661
34,992
42,965
72,345
68,520
49,744
30,863
2,357
28,451
29,983
74,361
60,200
81,309
113,663
142,304
79,655
51,704
287,057
269,811
210,647
210,647269,811287,05751,70479,655142,304113,66381,30960,20074,36129,98328,4512,35730,86349,74468,52072,34542,96534,99221,66125,88624,04665,63495,40135,82939,42441,97258,05660,94439,59744,09735,04532,30635,89842,85429,11728,81723,74536,98233,71330,93943,681101,02435,26120,09932,29061,81558,64966,0119,8548,49613,55311,88110,12955,8315,7235,0830014,60217,79628,96634,077
       Short-term Investments 
6,286
3,503
0
0
0
0
0
0
21,869
54,222
47,049
39,914
30,382
28,018
20,147
21,362
17,755
28,136
43,580
49,083
42,123
51,063
64,324
81,588
79,424
76,181
68,253
65,855
52,365
50,512
38,941
24,385
6,183
2,434
1,430
5,080
5,282
996
0
0
9,499
44,815
36,875
36,978
13,493
2,431
0
0
0
0
0
0
0
136,850
124,968
84,475
40,874
0
49,195
63,191
175,225
124,902
155,683
155,683124,902175,22563,19149,195040,87484,475124,968136,85000000002,43113,49336,97836,87544,8159,499009965,2825,0801,4302,4346,18324,38538,94150,51252,36565,85568,25376,18179,42481,58864,32451,06342,12349,08343,58028,13617,75521,36220,14728,01830,38239,91447,04954,22221,8690000003,5036,286
       Net Receivables 
1,900
2,495
4,706
8,690
0
0
6,886
8,100
7,457
10,316
8,966
9,253
9,764
9,612
10,654
12,900
10,056
10,839
12,413
10,552
18,790
13,329
16,919
22,384
19,577
21,786
26,248
25,457
19,643
18,885
12,835
14,610
14,391
13,659
13,732
15,049
16,267
16,874
18,379
16,651
19,309
19,262
14,014
18,981
14,410
9,983
25,069
25,423
15,412
15,666
13,732
18,320
15,422
10,937
17,294
17,280
14,504
15,119
16,560
19,660
36,012
32,441
35,317
35,31732,44136,01219,66016,56015,11914,50417,28017,29410,93715,42218,32013,73215,66615,41225,42325,0699,98314,41018,98114,01419,26219,30916,65118,37916,87416,26715,04913,73213,65914,39114,61012,83518,88519,64325,45726,24821,78619,57722,38416,91913,32918,79010,55212,41310,83910,05612,90010,6549,6129,7649,2538,96610,3167,4578,1006,886008,6904,7062,4951,900
       Inventory 
5,498
6,980
5,456
3,945
0
0
5,568
4,893
4,653
4,850
5,836
5,970
6,444
6,610
7,219
7,169
7,371
7,233
8,021
8,148
13,426
16,357
16,960
15,991
17,394
18,817
19,141
17,924
19,570
18,180
20,838
20,114
19,715
18,765
17,746
15,088
15,253
15,251
15,424
13,003
13,754
14,269
14,998
13,884
16,294
18,900
19,560
19,689
21,892
25,074
24,498
20,825
23,245
22,791
21,946
21,473
22,513
22,080
21,927
20,533
40,359
42,618
42,644
42,64442,61840,35920,53321,92722,08022,51321,47321,94622,79123,24520,82524,49825,07421,89219,68919,56018,90016,29413,88414,99814,26913,75413,00315,42415,25115,25315,08817,74618,76519,71520,11420,83818,18019,57017,92419,14118,81717,39415,99116,96016,35713,4268,1488,0217,2337,3717,1697,2196,6106,4445,9705,8364,8504,6534,8935,568003,9455,4566,9805,498
       Other Current Assets 
2,568
2,451
1,267
1,246
0
0
723
2,165
1,033
1,472
2,300
1,343
1,569
1,603
1,513
1,131
1,560
2,044
2,545
1,540
3,450
3,004
3,678
2,221
1,856
2,851
2,991
5,742
3,372
3,569
3,167
2,517
1,726
4,670
2,314
1,528
2,227
2,702
2,228
2,051
3,282
4,387
4,781
4,592
3,244
4,171
5,689
4,031
9,279
6,603
5,926
4,470
4,547
5,938
4,609
4,278
3,374
3,567
3,404
3,127
8,912
10,257
9,316
9,31610,2578,9123,1273,4043,5673,3744,2784,6095,9384,5474,4705,9266,6039,2794,0315,6894,1713,2444,5924,7814,3873,2822,0512,2282,7022,2271,5282,3144,6701,7262,5173,1673,5693,3725,7422,9912,8511,8562,2213,6783,0043,4501,5402,5452,0441,5601,1311,5131,6031,5691,3432,3001,4721,0332,165723001,2461,2672,4512,568
   > Long-term Assets 
4,447
5,283
3,129
3,670
0
0
3,830
3,920
3,875
4,666
6,570
9,293
14,011
9,235
11,551
12,521
14,680
31,423
27,583
12,331
245,910
290,312
277,573
251,662
239,798
245,749
233,037
226,966
216,631
214,990
212,334
209,724
206,356
199,584
195,830
192,550
188,701
183,856
180,430
176,541
179,969
177,014
172,840
168,716
207,786
203,898
200,314
207,094
208,871
211,109
6
203,148
198,741
190,245
185,898
181,495
176,726
172,757
168,544
164,852
230,102
228,703
227,932
227,932228,703230,102164,852168,544172,757176,726181,495185,898190,245198,741203,1486211,109208,871207,094200,314203,898207,786168,716172,840177,014179,969176,541180,430183,856188,701192,550195,830199,584206,356209,724212,334214,990216,631226,966233,037245,749239,798251,662277,573290,312245,91012,33127,58331,42314,68012,52111,5519,23514,0119,2936,5704,6663,8753,9203,830003,6703,1295,2834,447
       Property Plant Equipment 
3,378
2,757
2,777
1,930
0
0
2,169
2,328
2,285
2,539
2,569
3,256
3,577
4,024
4,308
4,974
5,019
4,919
5,155
6,818
9,377
11,568
12,668
13,889
14,053
14,102
14,358
15,258
15,370
16,816
17,305
16,525
15,258
13,966
13,335
12,301
11,433
10,424
9,760
8,825
15,411
14,804
13,748
12,916
47,642
46,892
46,000
55,645
61,029
66,435
6
65,153
64,088
62,687
61,310
59,535
57,976
56,716
55,729
54,850
77,752
74,100
72,246
72,24674,10077,75254,85055,72956,71657,97659,53561,31062,68764,08865,153666,43561,02955,64546,00046,89247,64212,91613,74814,80415,4118,8259,76010,42411,43312,30113,33513,96615,25816,52517,30516,81615,37015,25814,35814,10214,05313,88912,66811,5689,3776,8185,1554,9195,0194,9744,3084,0243,5773,2562,5692,5392,2852,3282,169001,9302,7772,7573,378
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
104,245
104,245
104,245
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
104,108
106,328
106,328
106,455
106,563
106,456
106,486
106,428
106,379
106,333
106,200
106,069
106,251
106,285
106,287
106,225
106,317
106,269
106,253
106,342
106,342106,253106,269106,317106,225106,287106,285106,251106,069106,200106,333106,379106,428106,486106,456106,563106,455106,328106,328104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,108104,245104,245104,24500000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
110,600
107,800
105,000
102,200
99,400
96,600
93,850
91,048
88,246
85,445
82,643
79,800
77,000
74,200
71,400
68,600
65,800
63,000
60,200
57,400
54,600
51,800
49,000
46,200
48,612
45,644
42,955
40,206
38,789
34,082
32,419
27,927
24,875
18,200
15,400
12,600
10,210
7,242
4,200
1,407
24,794
24,078
23,367
23,36724,07824,7941,4074,2007,24210,21012,60015,40018,20024,87527,92732,41934,08238,78940,20642,95545,64448,61246,20049,00051,80054,60057,40060,20063,00065,80068,60071,40074,20077,00079,80082,64385,44588,24691,04893,85096,60099,400102,200105,000107,800110,60000000000000000000000
       Long-term Assets Other 
1,069
2,526
352
1,740
0
0
321
252
250
787
2,661
3,197
4,369
4,210
4,041
3,881
2,363
3,431
3,288
3,571
6,558
4,405
3,698
3,966
3,729
3,820
3,688
10,059
8,907
8,621
8,278
9,291
9,990
7,310
6,987
7,541
7,360
6,324
6,362
6,208
5,850
6,302
5,984
5,492
5,204
5,034
4,904
4,680
2,597
4,106
3,265
31,616
3,445
3,158
3,119
3,109
2,255
2,512
2,390
1,478
15,635
19,234
25,977
25,97719,23415,6351,4782,3902,5122,2553,1093,1193,1583,44531,6163,2654,1062,5974,6804,9045,0345,2045,4925,9846,3025,8506,2086,3626,3247,3607,5416,9877,3109,9909,2918,2788,6218,90710,0593,6883,8203,7293,9663,6984,4056,5583,5713,2883,4312,3633,8814,0414,2104,3693,1972,661787250252321001,7403522,5261,069
> Total Liabilities 
185,107
194,586
190,693
205,772
0
0
23,539
213,968
25,955
23,350
23,451
22,429
18,768
16,012
14,436
13,075
13,113
13,580
17,229
19,797
257,292
255,920
255,838
257,140
252,578
255,912
254,361
256,160
255,458
257,770
252,449
253,162
253,965
254,772
252,926
256,416
221,128
224,270
229,878
231,531
109,202
111,153
106,789
111,200
148,723
149,629
171,004
185,707
182,260
179,865
182,851
180,618
249,825
478,576
477,662
471,777
468,807
469,214
471,005
159,865
200,351
198,471
192,206
192,206198,471200,351159,865471,005469,214468,807471,777477,662478,576249,825180,618182,851179,865182,260185,707171,004149,629148,723111,200106,789111,153109,202231,531229,878224,270221,128256,416252,926254,772253,965253,162252,449257,770255,458256,160254,361255,912252,578257,140255,838255,920257,29219,79717,22913,58013,11313,07514,43616,01218,76822,42923,45123,35025,955213,96823,53900205,772190,693194,586185,107
   > Total Current Liabilities 
11,575
15,751
8,521
7,129
0
0
11,443
18,512
18,545
17,759
19,662
20,171
17,743
14,766
13,125
11,597
11,537
11,626
15,043
17,248
25,736
27,306
27,306
29,385
24,904
28,930
27,481
30,081
30,520
32,315
27,915
29,500
31,289
34,324
31,884
33,474
33,704
36,650
38,865
37,582
34,182
37,320
33,366
32,821
35,364
38,348
42,791
54,249
53,529
52,848
47,290
49,568
47,173
42,770
46,169
43,443
43,787
46,840
51,800
109,327
121,554
123,808
120,615
120,615123,808121,554109,32751,80046,84043,78743,44346,16942,77047,17349,56847,29052,84853,52954,24942,79138,34835,36432,82133,36637,32034,18237,58238,86536,65033,70433,47431,88434,32431,28929,50027,91532,31530,52030,08127,48128,93024,90429,38527,30627,30625,73617,24815,04311,62611,53711,59713,12514,76617,74320,17119,66217,75918,54518,51211,443007,1298,52115,75111,575
       Short-term Debt 
3,834
6,081
1,034
3,531
0
0
3,020
7,686
7,995
8,310
8,601
8,921
6,343
4,703
1,875
0
0
0
0
703
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,701
3,350
2,363
1,833
1,185
2,170
2,697
2,973
3,025
2,971
2,873
9,891
3,209
3,293
4,348
5,765
7,097
8,495
8,980
63,853
66,324
66,485
61,035
61,03566,48566,32463,8538,9808,4957,0975,7654,3483,2933,2099,8912,8732,9713,0252,9732,6972,1701,1851,8332,3633,3503,7010000000000000000000070300001,8754,7036,3438,9218,6018,3107,9957,6863,020003,5311,0346,0813,834
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,838
0
0
833
2,083
3,333
4,583
5,000
59,530
54,656
54,783
54,913
54,91354,78354,65659,5305,0004,5833,3332,083833006,838000000000000000000000000000000000000000000000000000
       Accounts payable 
2,725
3,231
2,860
2,224
0
0
1,805
3,155
4,673
2,983
4,679
4,010
4,101
3,295
3,345
2,555
3,214
1,997
3,406
4,353
8,001
7,637
7,276
5,919
5,502
5,964
6,303
6,094
4,439
5,830
4,871
3,967
3,731
3,858
4,721
4,211
5,206
6,642
6,246
4,027
6,936
8,075
5,339
6,510
9,440
9,384
10,971
9,220
12,552
11,224
10,786
10,602
12,517
9,016
9,305
7,914
6,109
6,089
7,327
9,236
13,141
12,570
10,926
10,92612,57013,1419,2367,3276,0896,1097,9149,3059,01612,51710,60210,78611,22412,5529,22010,9719,3849,4406,5105,3398,0756,9364,0276,2466,6425,2064,2114,7213,8583,7313,9674,8715,8304,4396,0946,3035,9645,5025,9197,2767,6378,0014,3533,4061,9973,2142,5553,3453,2954,1014,0104,6792,9834,6733,1551,805002,2242,8603,2312,725
       Other Current Liabilities 
2,364
3,935
3,215
616
0
0
5,128
6,335
4,315
4,680
4,564
5,229
5,772
5,035
5,771
7,156
6,395
7,412
8,830
10,877
12,404
13,802
13,400
16,538
12,056
15,419
12,999
14,568
16,980
17,457
13,320
16,370
17,658
21,369
17,286
19,025
17,853
19,252
21,108
22,091
11,220
13,923
13,726
12,675
12,072
12,515
15,687
28,581
23,730
16,975
16,474
27,019
15,553
15,323
17,538
15,328
15,308
16,941
20,622
20,572
28,183
29,640
35,218
35,21829,64028,18320,57220,62216,94115,30815,32817,53815,32315,55327,01916,47416,97523,73028,58115,68712,51512,07212,67513,72613,92311,22022,09121,10819,25217,85319,02517,28621,36917,65816,37013,32017,45716,98014,56812,99915,41912,05616,53813,40013,80212,40410,8778,8307,4126,3957,1565,7715,0355,7725,2294,5644,6804,3156,3355,128006163,2153,9352,364
   > Long-term Liabilities 
173,532
178,835
182,172
198,643
0
0
12,096
195,456
7,410
5,591
3,789
2,258
1,025
1,246
1,311
1,478
1,576
1,954
2,186
2,549
231,556
228,614
228,532
227,755
227,674
226,982
226,880
226,079
224,938
225,455
224,534
223,662
222,676
220,448
221,042
222,942
187,424
187,620
191,013
193,949
75,020
73,833
73,423
78,379
113,359
111,281
128,213
131,458
128,731
127,017
135,561
131,050
202,652
435,806
431,493
428,334
425,020
422,374
419,205
50,538
78,797
74,663
71,591
71,59174,66378,79750,538419,205422,374425,020428,334431,493435,806202,652131,050135,561127,017128,731131,458128,213111,281113,35978,37973,42373,83375,020193,949191,013187,620187,424222,942221,042220,448222,676223,662224,534225,455224,938226,079226,880226,982227,674227,755228,532228,614231,5562,5492,1861,9541,5761,4781,3111,2461,0252,2583,7895,5917,410195,45612,09600198,643182,172178,835173,532
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
53,943
64,044
64,209
100,032
54,384
63,885
62,809
61,734
60,662
59,590
0
0
0
0
000059,59060,66261,73462,80963,88554,384100,03264,20964,04453,9430000000000000000000000000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
311,253
311,253
311,253
311,253
311,253
0
0
0
0
0
00000311,253311,253311,253311,253311,25300000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,013
33,347
29,293
65,860
24,275
21,486
20,191
0
18,228
0
0
0
0
0
0000018,228020,19121,48624,27565,86029,29333,34734,0130000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
620
0
1,052
1,049
0
0
0
0
0
000001,0491,0520620000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
-130,331
-144,908
-158,339
-173,619
0
0
-1,449
-189,167
68,763
62,305
59,151
56,897
51,898
48,920
102,659
100,657
100,124
98,385
97,012
97,118
167,431
161,826
154,555
150,419
142,453
133,217
124,126
114,901
98,977
84,264
67,972
53,233
38,503
23,937
39,070
30,935
48,574
34,833
22,412
72,116
182,245
172,640
162,605
153,612
141,496
132,719
151,973
139,050
122,938
109,450
99,337
94,596
22,113
-37,454
-62,747
-81,467
-97,153
-113,387
-131,720
163,202
577,316
510,261
489,333
489,333510,261577,316163,202-131,720-113,387-97,153-81,467-62,747-37,45422,11394,59699,337109,450122,938139,050151,973132,719141,496153,612162,605172,640182,24572,11622,41234,83348,57430,93539,07023,93738,50353,23367,97284,26498,977114,901124,126133,217142,453150,419154,555161,826167,43197,11897,01298,385100,124100,657102,65948,92051,89856,89759,15162,30568,763-189,167-1,44900-173,619-158,339-144,908-130,331
   Common Stock
10
10
2
2
0
0
13
2
20
20
20
20
20
21
25
25
25
25
26
26
28
28
28
28
29
29
29
29
29
29
29
29
29
29
39
39
39
39
39
49
69
69
70
70
71
71
74
75
75
76
76
77
77
79
79
80
80
81
82
83
387
389
390
3903893878382818080797977777676757574717170706969493939393939292929292929292929292828282826262525252521202020202021300221010
   Retained Earnings -1,151,579-1,124,641-1,078,923-1,000,752-980,976-959,979-942,939-926,096-905,251-875,825-812,286-735,998-726,568-712,725-695,582-676,761-658,735-652,736-639,721-623,641-610,956-598,069-584,316-558,851-544,075-529,325-513,084-500,196-489,738-473,795-456,862-439,477-421,781-401,993-383,375-363,492-350,613-341,344-326,108-310,177-299,233-285,443-272,761-257,347-252,704-248,418-244,373-240,821-237,219-233,067-228,487-221,797-218,340-213,851-206,665-199,327-196,24900-182,425-163,297-149,060-133,798
   Accumulated Other Comprehensive Income 
-135
-241
-556
-504
0
0
-752
-778
-790
-774
-742
-754
-777
-782
-774
-769
-772
-795
-713
-730
-757
-700
-802
-794
-600
-697
-794
-1,144
-885
-858
-911
-760
-725
-648
-731
-574
-532
-504
-516
-687
-677
-623
-758
-582
-885
-809
-289
112
-331
-284
-730
-907
-1,057
-2,253
-2,609
-1,896
-1,328
-1,551
-1,949
-2,221
-1,792
-1,500
-1,409
-1,409-1,500-1,792-2,221-1,949-1,551-1,328-1,896-2,609-2,253-1,057-907-730-284-331112-289-809-885-582-758-623-677-687-516-504-532-574-731-648-725-760-911-858-885-1,144-794-697-600-794-802-700-757-730-713-795-772-769-774-782-777-754-742-774-790-778-75200-504-556-241-135
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
822,383
826,559
831,424
835,379
840,545
845,034
847,008
850,063
853,466
856,926
0
0
0
0
0000856,926853,466850,063847,008845,034840,545835,379831,424826,559822,3830000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
3,592
4,383
5,512
9,308
0
0
195,539
9,884
181,480
191,255
195,611
200,102
281,142
282,748
340,627
342,222
345,244
347,573
350,403
354,465
440,921
447,941
454,562
461,362
469,132
475,229
475,504
479,508
483,208
487,086
490,635
493,441
496,061
498,351
529,500
531,666
562,151
564,623
566,964
631,605
767,169
771,263
774,249
777,765
782,031
786,193
810,923
815,624
818,776
822,383
826,559
94,596
797,587
529,292
533,781
535,192
535,781
536,809
539,870
854,839
1,657,644
1,636,013
1,641,931
1,641,9311,636,0131,657,644854,839539,870536,809535,781535,192533,781529,292797,58794,596826,559822,383818,776815,624810,923786,193782,031777,765774,249771,263767,169631,605566,964564,623562,151531,666529,500498,351496,061493,441490,635487,086483,208479,508475,504475,229469,132461,362454,562447,941440,921354,465350,403347,573345,244342,222340,627282,748281,142200,102195,611191,255181,4809,884195,539009,3085,5124,3833,592



5.3. Balance Sheets

Currency in USD. All numbers in thousands.